Concord Drugs Ltd

Concord Drugs Ltd is sending a letter to members whose email addresses are not registered, providing a web link and path to access the Annual Report for the Financial Year 2025-26. This action is in compliance with Regulation 36(1)(b) of SEBI LODR Regulations. The Annual Report is also available on the company's website. The company is also reminding shareholders to update their email addresses for efficient communication.

Concord Drugs Limited has announced its 31st Annual General Meeting (AGM) scheduled for September 30, 2026, to be held via Video Conferencing. The company has also released its Annual Report for the Financial Year 2025-26. The Register of Members and Share Transfer Books will be closed from September 24 to September 30, 2026, for the AGM. The record date for determining eligible members for e-voting has been set as September 23, 2026. The Annual Report is available on the company's website and the BSE.

Concord Drugs Ltd has announced book closure for its 31st Annual General Meeting (AGM) scheduled for September 30, 2026. The company's Register of Members and Share Transfer Books will be closed from September 24, 2026, to September 30, 2026, inclusive. The record date for determining eligible shareholders for electronic voting has been set as September 23, 2026. The AGM will be conducted via Video Conference/Other Audio-Visual Means.

Concord Drugs Limited has announced the record date for its 31st Annual General Meeting (AGM) as September 23, 2026. The company's Register of Members and Share Transfer Books will be closed from September 24 to September 30, 2026, inclusive. The AGM is scheduled for September 30, 2026, at 09:30 AM, to be conducted via Video Conference/Other Audio-Visual Means. This record date is crucial for determining eligible shareholders for voting purposes.

Concord Drugs Ltd announced that its Board of Directors has approved the notice and proposed to hold the 31st Annual General Meeting (AGM) on September 30, 2026. The AGM will be conducted via Video Conferencing / Other Audio Visual Means. The Board also approved the Directors' Report and Annual Report for the financial year 2025-26. Key agenda items include the adoption of audited standalone and consolidated financial statements, re-appointment of directors retiring by rotation and independent directors, re-appointment of statutory auditors for a five-year term, and ratification of cost auditor remuneration. The company also approved seeking member approval for material related party transactions for FY 2026-27.

Concord Drugs Ltd has announced that its Annual General Meeting (AGM) will be held on September 30, 2026, at 09:30 AM. The meeting will be conducted via Video Conference/Other Audio-Visual Means, in compliance with MCA and SEBI circulars. The company is also submitting its Annual Report and Notice of AGM for the Financial Year 2025-26, which will be sent electronically to members with registered email addresses. A weblink to access the Annual Report will be provided to members whose email addresses are not registered. The AGM will transact ordinary business, including the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026.

Concord Drugs Ltd announced the outcome of its Board meeting held on August 10, 2026. The Board considered and approved the Un-Audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. A Limited Review Report from the Statutory Auditors was also noted. The financial results are available on the company's website and will be published in newspapers as per SEBI regulations. The meeting commenced at 4:00 PM and concluded at 5:00 PM.

Concord Drugs Ltd announced that its Board of Directors has approved the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The board meeting took place on August 10, 2026. The company also noted the Limited Review Report from its statutory auditors. The financial results are available on the company's website and will be published in newspapers as per SEBI regulations. The meeting commenced at 4:00 PM and concluded at 5:00 PM.

Concord Drugs Ltd has announced that its Board of Directors will convene on August 10, 2026, to consider and approve the unaudited financial results for the first quarter ended June 30, 2026. The meeting will cover both standalone and consolidated results. Additionally, the company has closed its trading window for designated persons and their relatives, effective until 48 hours after the financial results are declared, in compliance with its insider trading code.

Concord Drugs Ltd has announced the closure of its trading window from July 1, 2026, until 48 hours after the declaration of its un-audited financial results for the quarter ending June 30, 2026. This measure, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, restricts directors, designated employees, insiders, and their immediate relatives from trading in the company's securities during this period. The specific date of the board meeting to consider these results will be communicated separately.